ScreenerHero
DMPDermapharm Holding SE
XETRA · DE · Healthcare · Drug Manufacturers - Specialty & Generic · ir.dermapharm.de
40.15EUR+0.63%Mkt Cap: 2.16B $P/E: 14.98

Dermapharm Holding SE, together with its subsidiaries, manufactures and sells off-patent branded pharmaceutical products in Germany, Italy, France, Austria, Switzerland, Spain, Portugal, the Netherlands, Croatia, Poland,…

Industry Peers

Drug Manufacturers - Specialty & Generic
Screen all
MRK
MERCK Kommanditgesellschaft auf Aktien
$65.24BUSDP/E 23.7
HLN
Haleon plc American Depositary Shares (Each representing two Ordinary Shares)
$43.41BUSDP/E 20.1
ZOE
Zoetis Inc.
$29.37BUSDP/E 12.4
UTHR
United Therapeutics Corporation
$22.70BUSDP/E 19.0
VTRS
Viatris, Inc.
$18.66BUSD
SOBI
Swedish Orphan Biovitrum AB
$15.39BUSDP/E 118.0
NBIX
Neurocrine Biosciences, Inc.
$15.81BUSDP/E 22.8
IPN
Ipsen S.A.
$14.67BUSDP/E 26.5
ELAN
Elanco Animal Health Incorporat
$12.24BUSD
KRK
Krka, d. d.
$8.57BUSDP/E 18.8
HIMS
Hims & Hers Health, Inc.
$7.25BUSD
LQDA
Liquidia Corporation
$6.74BUSDP/E 53.8
LNTH
Lantheus Holdings Inc
$6.56BUSDP/E 24.0
AMRX
Amneal Pharmaceuticals, Inc.
$6.23BUSDP/E 37.3
INDV
Indivior PLC Ordinary Shares
$4.61BUSDP/E 14.0
HIK
Hikma Pharmaceuticals PLC
$4.32BUSDP/E 12.5
AMLX
Amylyx Pharmaceuticals Inc. Common Stock
$4.30BUSD
SFZN
Siegfried Holding AG
$3.91BUSDP/E 20.4
ROVI
Laboratorios Farmaceuticos Rovi, S.A.
$3.34BUSDP/E 16.6
SUPN
Supernus Pharmaceuticals, Inc.
$2.82BUSD

Key Statistics

Company
Market Cap2.16B $
Enterprise Value3.21B $
Revenue (TTM)1.29B $
Gross Profit851.01M $
Net Income (TTM)143.93M $
Revenue/Share23.88 USD
Last Price40.15 EUR
Fiscal Year EndDec 2025
MR QuarterMar 2026
Employees3.5K
CountryDE
SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic
ISINDE000A2GS5D8
Valuation
P/E (Trailing)14.98
P/E (Forward)13.56
PEG—
EV/EBITDA10.90
EV/Revenue2.50
P/S1.66
P/B2.89
EPS (TTM)2.68
EPS (Forward)2.93
52W Range
31.7042% of range51.90
52W High51.90 EUR
52W Low31.70 EUR
Profitability
Gross Margin67.21%
Oper. Margin19.68%
EBITDA Margin22.96%
Profit Margin11.37%
ROE19.07%
ROA6.06%
Growth
Revenue Growth1.30%
Earnings Growth35.50%
Cash Flow & Leverage
Operating CF249.07M $
CapEx (TTM)45.78M $
FCF Margin13.56%
FCF Yield8.06%
Net Debt884.28M $
Net Debt/EBITDA3.00
Balance Sheet
Debt/Equity1.52
Current Ratio2.00
Quick Ratio0.93
Book Value/Sh13.73 EUR
Cash/Share4.199 EUR
Dividends
Fwd Div Rate0.8800 EUR
Trail. Div Rate0.8800 EUR
Div. Yield2.21%
5Y Avg Yield2.83%
Payout Ratio33.58%
Ex-Div DateJun 29, 2026
Pay Date—
Analyst Consensus
Rating2.0 (Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)50.38 EUR
Upside (mean)+25.5%
Target Range44.00 EUR – 60.00 EUR
€44.00+25.5% to mean€60.00
# Analysts4
Ownership
Shares Out.49.54M
Float7.04M
Insiders89.30%
Institutions8.23%
Technical
SMA 5043.66 (-8.0%)
SMA 20041.74 (-3.8%)
Beta0.85
S&P 52W Chg18.16%
Avg Vol (30d)23.75K
Avg Vol (10d)26.36K
Technical Indicators
RSI (14)36.4
MACD-1.0543
MACD Signal-1.1740
MACD Hist.+0.1197
BB Upper42.32 EUR
BB Middle40.69 EUR
BB Lower39.05 EUR
BB Width8.03%
ATR (14)1.083 EUR
Vol Ratio (20d)1.20x